Solural Pharma ApS publish phase 1 clinical results of its oral irinotecan product in Cancer Chemotherapy and Pharmacology: Oral administration of Irinotecan in patients with solid tumor: An open label phase 1, dose escalation study evaluating safety, tolerability and pharmacokinetics